Drilldown: Medicines

Other values:

Search

None (10) · Akineton (1) · Apokyn (1) · Artane (1) · Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs (1) · Azilect (1) · Cogentin (1) · Comtan (1) · Dalmane (1) · Doral (1) · Dostinex (1) · Eldepryl (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Neupro (1) · Onfi (1) · Ongentys (1) · Parlodel (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Sinemet (1) · Symmetrel (1) · Tasmar (1) · Tranxene (1) · Versed (1) · Xadago (1) · Xanax (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Irreversible selective MAO-B inhibitor (2) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Selective M1 muscarinic antagonist (1) · '"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'. (1)

None (38) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"' (1)

None (38) · 0.25 mg (1) · POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d (1)

None (38) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT (1)

None (38) · 10 mg/d (1) · Indication-specific (1)

None (38) · Oral (2)

None (38) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Contraception within 48 hours of starting (POP); endometrial effects days (1)

None (38) · 6 h (immediate-release); ~11 h (extended-release) (1) · ~24 hours per dose (strict timing required for POP — within 3-hour window each day) (1)

None (38) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~8 hours'"`UNIQ--ref-000013F5-QINU`"' (1)

None (38) · 80-90% oral (1) · ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' (1)

None (38) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (38) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx) (1)